Metastatic HER2 positive breast cancer Epidemiology Forecast

· The total incident cases of HER2-positive breast cancer in the United States comprised approximately 44,000 cases in 2023 and are projected to increase during the forecasted period (2024–2034).

· In Germany, approximately 53% of HER2-positive breast cancer cases were observed in the age group of 40–60 years in 2023, followed by the age group of 60–75 years.

· In 2023, Stage II HER2-positive breast cancer accounted for the maximum patient share in stage-specific cases of HER2-positive breast cancer in the 7MM, i.e., nearly 40%, followed by Stage I.

· In Japan, around 4,300 cases were under metastatic HER2-positive breast cancer cases.

· HR+/HER2+ accounted for the maximum number of cases of HER2-positive breast cancer by hormonal status in the 7MM, which was roughly 69,000 cases in 2023.

· In the US, from the mid-2000s, invasive breast cancer in women has increased by approximately 0.5% yearly. This is likely caused by increased excess body weight in women, a drop in fertility rates, and rising age for first births.

· The incidence of breast cancer in Germany is expected to rise in the future, primarily because of the aging population and shifts in reproductive patterns. These shifts encompass more women without children, delayed first-time motherhood, reduced breastfeeding rates, and lifestyle modifications, encompassing dietary and exercise habits.

· In France, invasive breast cancer increased annually by ~0.8% in all age groups combined from 1990 to 2018.

· In Japan, there is a marked and ongoing increase in the incidence of breast cancer. While the specific reasons for this rise remain uncertain, it is well-established that female hormones play a pivotal role in the development and growth of breast cancer. Additionally, the genetic background of individuals is closely intertwined with their susceptibility to this disease.

DelveInsight’s “Metastatic HER2-positive Breast Cancer – Epidemiology Forecast – 2034” report delivers an in-depth understanding of HER2-positive breast cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

· The United States

· EU4 (Germany, France, Italy, and Spain) and the United Kingdom

· Japan

Study Period: 2020-2034

Metastatic HER2-positive Breast Cancer Disease Understanding

HER2-positive Breast Cancer Overview

Breast cancer initiates when abnormal cancerous cells in the breast grow and proliferate, creating a tumor. It usually starts in the ducts or lobules of the breast.

Some breast cancers depend on the human epidermal growth factor receptor 2 (HER2) gene to grow. These cancers are called HER2+ and have many copies of the HER2 gene or high levels of the HER2 protein. These proteins are also called “receptors.” The HER2 gene makes the HER2 protein found in cancer cells and is important for tumor cell growth. Human epidermal growth factor receptor-2 positive (HER2+) is breast cancer that tests positive for the HER2 protein. HER2+ breast cancer grows faster and is more likely to spread and return than human epidermal growth factor receptor-2 negative (HER2−) breast cancer. Patients’ HER2 status is determined by whether breast cancer tests are positive or negative for the HER2 protein.

Metastatic HER2-positive Breast Cancer Diagnosis

Various tests such as tumor mutation testing: MSI-H/dMMR mutation, PD-1, and PD-L1 testing, FISH (Fluorescence in Situ Hybridization), Immunohistochemistry (IHC), Next-generation sequencing, Polymerase chain reaction, and genetic risk testing: BRCA tests are employed to determine the presence of HER2-positive breast cancer. The appearance of results in the report will vary based on the specific test conducted. Two widely used tests are the IHC (ImmunoHistoChemistry) and the FISH (Fluorescence in Situ Hybridization).

It is important to know which HER2 test the patient had. Generally, only cancers that test IHC 3+ or FISH positive respond to the medicines that target HER2-positive breast cancers. An IHC 2+ test result is called borderline. If the patient has an IHC 2+ result, ask to retest the tissue with the FISH test.

Further details related to diagnosis will be provided in the report…

Metastatic HER2-positive Breast Cancer Epidemiology

The HER2-positive breast cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incidence of breast cancer, total incident cases of HER2-positive breast cancer, hormonal status of HER2-positive breast cancer, age-specific cases of HER2-positive breast cancer, stage-specific cases of HER2-positive breast cancer, and line wise metastatic cases of HER2-positive breast cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

· According to the estimates, the total incident population of HER2-positive breast cancer in the seven major markets was nearly 102,000 cases in 2023. The cases in the 7MM are expected to increase during the forecast period, i.e., 2024–2034.

· The HR+/HER2+ breast cases were highest in the United States, accounting for ~32,000 cases.

· According to the estimates, most cases of HER2-positive breast cancer occur in people between 40 and 60 in the United States, accounting for ~52% of total cases in 2023.

· Among EU4 and the UK, Germany had the maximum total incident cases of HER2-positive breast cancer, with ~11,000 cases in 2023, while Spain accounted for the least number of cases.

· In Japan, stage-specific cases of HER2-positive breast cancer were highest in Stage II, accounting for ~6,000 cases in 2023.

KOL- Views

To keep up with current epidemiology trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the HER2-positive breast cancer epidemiology, including oncologists, radiation oncologists, and surgical oncologists.

DelveInsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Institute for Personalized Cancer Therapy, Aichi Cancer Center, University Hospital Ulm, Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or HER2-positive breast cancer epidemiology trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the epidemiology and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of HER2-positive breast cancer, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
• Comprehensive insight into the epidemiology segments and forecasts, the future HER2-positive breast cancer market growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of the HER2-positive breast cancer epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Metastatic HER2-positive Breast Cancer Report Insights

• Patient Population
• Patient population by gender, stage, and age
• Country-wise Epidemiology Distribution

Metastatic HER2-positive Breast Cancer Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• HER2-positive Breast Cancer Epidemiology Segmentation

Metastatic HER2-positive Breast Cancer Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights:

• What are the disease risks and burdens of HER2-positive breast cancer? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HER2-positive breast cancer?
• What is the historical and forecasted HER2-positive breast cancer patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which age group is the largest contributor in patients with HER2-positive breast cancer?
• What factors affect the increase in the number of HER2-positive breast cancer therapy patients?
• Which clinical stage has the highest patient number in HER2-positive breast cancer?
• At what CAGR is the population expected to grow across the 7MM during the study period (2020–2034)?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Stay Updated with us for Recent Articles:-

• Metastatic HER2-Positive Breast Cancer
• Estrogen Receptor Positive Breast Cancer: Market Outlook
• Global HR+/ HER2- Breast Cancer Market Scenario
• How HR+/ HER2- Breast Cancer Emerging Drugs Will Transform the Market?
• HR-positive/ HER2-negative Breast Cancer Market Insights: Upcoming Therapies and Market Analysis
• Breast Cancer: Understand Your Breasts, Recognize the Symptoms
• Key Facts To Know About Triple-Negative Breast Cancer In The Breast Cancer Awareness Month
• 7 Most Common Myths About Breast Cancer Demystified
• Roche’s HER2-Positive Breast Cancer Treatment Franchise
• Latest DelveInsight Blogs